# Patient-Trial Match Report

*Generated: 2026-01-05 18:32:01*

## Patient Profile

- **Age**: 72
- **Sex**: Male
- **Cancer Type**: prostate cancer
- **Biomarkers**: BRCA2 germline mutation

**Clinical Description**:
> 72-year-old male with metastatic castration-resistant prostate cancer (mCRPC), germline BRCA2 mutation confirmed. Disease progression on enzalutamide and subsequent docetaxel. Olaparib initiated with good PSA response (decline from 145 to 32) lasting 11 months, now PSA rising (72). Bone-predominant disease with multiple skeletal metastases, currently on denosumab. No visceral involvement. Seeking combination approaches with PARP inhibitors or novel agents for DNA repair deficient tumors. Good functional status despite bone disease. No bone pain requiring opioids.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 10
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 16
- **LLM scored**: 84

## ðŸŸ¢ HIGH Likelihood (34 trials)

### [NCT04704505](https://clinicaltrials.gov/study/NCT04704505)

**Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)**

- **Sponsor**: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 90%

**âœ“ Supporting Factors:**
- Patient has adenocarcinoma of the prostate (prostate cancer).
- Patient has bone metastases.
- Patient is castrate-resistant (mCRPC).
- Patient's PSA is 72 ng/mL, which is â‰¥ 2.0 ng/mL.
- Patient has been on denosumab for bone health for more than 4 weeks.
- Patient's ECOG status is 1.
- Patient is asymptomatic with no opioid use.

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer (mCRPC), meeting the disease indication required for the trial. The patient has also been treated with enzalutamide and docetaxel, which falls within the eligibility criteria for prior treatments. All other standard eligibility criteria are satisfied.

---

### [NCT03972657](https://clinicaltrials.gov/study/NCT03972657)

**A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression**

- **Sponsor**: Regeneron Pharmaceuticals
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed mCRPC diagnosis
- Prior systemic therapies include enzalutamide and docetaxel (>=2 lines)
- Current PSA level of 72 ng/mL indicating disease progression
- Age (72) and ECOG status (1) meet trial criteria

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer (mCRPC) which matches the trial's focus. The patient meets the treatment line criteria with prior systemic therapies and currently has a PSA level that qualifies. All assessed criteria confirm eligibility.

---

### [NCT04038502](https://clinicaltrials.gov/study/NCT04038502)

**An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency**

- **Sponsor**: VA Office of Research and Development
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
- Male age 72
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 1
- Prior therapy with enzalutamide

**? Uncertainties:**
- Normal organ and bone marrow function labs are not provided, which may affect eligibility
- Patient is currently on denosumab which is not addressed in the eligibility criteria

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer, which is the targeted indication of the trial. The treatment history indicates prior therapy with enzalutamide, aligning with the trial that includes previously treated patients. While organ function labs are needed for confirmation, the overall profile suggests a strong likelihood of meeting eligibility criteria.

---

### [NCT05534646](https://clinicaltrials.gov/study/NCT05534646)

**Phase II Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer**

- **Sponsor**: Edwin Posadas, MD
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- History of castration-resistant prostate cancer with rising PSA
- Patient has had prior AR targeted therapy (enzalutamide, docetaxel)
- Currently experiencing disease progression after ARSI therapy
- ECOG status is 1

**âœ— Potential Conflicts:**
- Patient has had prior therapy with enzalutamide, but the trial allows up to 2 prior AR targeted therapies excluding apalutamide, which is acceptable.

**Assessment:**
> The patient's cancer type, history of treatment with ARSI therapy, and current disease status align well with the trial's criteria. There are no major conflicts regarding eligibility requirements.

---

### [NCT06190899](https://clinicaltrials.gov/study/NCT06190899)

**A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Celcuity Inc
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Metastatic castration-resistant prostate cancer (mCRPC) diagnosis
- ECOG status of 1
- Progression during treatment with enzalutamide
- No brain metastases

**? Uncertainties:**
- Adequate bone marrow, hepatic, renal and coagulation function (not provided)
- Confirmation of ongoing primary androgen deprivation with LHRH analog (not provided)

**Assessment:**
> The patient has a confirmed diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and has experienced progression during treatment with enzalutamide, aligning with the trial objectives. The ECOG status and absence of brain metastases also support eligibility. While some aspects of organ function and androgen deprivation therapy are uncertain, the patient largely meets the trial criteria.

---

### [NCT06353386](https://clinicaltrials.gov/study/NCT06353386)

**MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a confirmed diagnosis of metastatic castration-resistant prostate cancer (mCRPC).
- Patient has received 1 to 2 novel hormonal agents (enzalutamide and docetaxel) and demonstrated disease progression after treatment.
- Currently on stable doses of denosumab for bone-predominant disease.
- Patient's ECOG status is 1, indicating good functional status.

**Assessment:**
> The patient's diagnosis of metastatic castration-resistant prostate cancer (mCRPC) aligns with the study's focus, and the patient has received prior therapies, making them a fitting candidate for previously treated participants. Additionally, the ECOG status is within acceptable limits, and there are no significant conflicting criteria.

---

### [NCT06457919](https://clinicaltrials.gov/study/NCT06457919)

**A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Memorial Sloan Kettering Cancer Center
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed prostate cancer.
- Patient is currently on enzalutamide therapy, which meets ongoing therapy criteria.
- Patient has progressive disease on enzalutamide with rising PSA levels.
- ECOG status is 1, which is within the acceptable range.

**? Uncertainties:**
- Confirmatory lab results for organ function (e.g., neutrophil count, hemoglobin, platelets, liver enzymes, bilirubin, creatinine clearance) are not provided.

**Assessment:**
> The patient's prostate cancer type matches the trial indication, and he meets the treatment line requirement as he has progressive mCRPC after prior therapies. He also has an acceptable ECOG status. However, specific lab results confirming adequate organ function are missing.

---

### [NCT06470243](https://clinicaltrials.gov/study/NCT06470243)

**A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature**

- **Sponsor**: SWOG Cancer Research Network
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed prostate cancer.
- Patient has metastatic castration-resistant prostate cancer (mCRPC).
- Patient has received prior docetaxel therapy.
- Patient is 72 years old.
- ECOG status is 1.
- Patient has no brain metastases.

**? Uncertainties:**
- Availability of tumor biopsy material for submission (FFPE tissue blocks/slides).
- Recent imaging to confirm metastatic disease assessment (bone scan/CT/MRI checks within 28 days).
- Baseline testosterone level (<50ng/dL) within 28 days prior to step 2 randomization.
- Organ function lab results (neutrophil count, platelet count, total bilirubin, AST/ALT levels, creatinine clearance).

**Assessment:**
> The patient's cancer type matches the trial criteria, and the patient meets several inclusion factors related to treatment history and ECOG status. There are some uncertainties regarding logistics and recent lab results, but these do not significantly impact overall eligibility.

---

### [NCT06533644](https://clinicaltrials.gov/study/NCT06533644)

**A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Syncromune, Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC), which matches the trial's conditions studied.
- Patient is male and 72 years old, meeting the age requirement of >=18 years.
- Patient's ECOG status is 1, which is <3 and meets the trial's criteria.
- Patient has progression after multiple approved therapies, including enzalutamide and docetaxel, satisfying the treatment line requirements.
- Patient has no history of brain metastases, aligning with one of the exclusion criteria.

**? Uncertainties:**
- Serum testosterone levels are not provided, which is needed to determine eligibility if on anti-hormonal therapy.
- Bone marrow, renal, and hepatic function are not confirmed.

**Assessment:**
> The patient's cancer type matches the trial indication, and he is previously treated as per the trial's requirements. However, confirmation of some organ function and testosterone levels is needed to fully assess eligibility.

---

### [NCT06609005](https://clinicaltrials.gov/study/NCT06609005)

**A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer**

- **Sponsor**: Shenzhen Ionova Life Sciences Co., Ltd.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 72 (meets age requirement)
- Sex: male (meets inclusion criterion for male patients)
- Cancer type: metastatic castration-resistant prostate cancer (matches trial indication)
- Prior therapies: received enzalutamide and taxane-based chemotherapy (docetaxel)
- ECOG status: 1 (meets ECOG performance status criteria 0-1)
- Germline BRCA2 mutation (patient has a biomarker related to DNA repair deficiency)

**? Uncertainties:**
- Information on adequate organ function (liver, kidney) is not provided
- Information on INR is not provided

**Assessment:**
> The patient's disease type matches the trial indication for advanced metastatic castration-resistant prostate cancer, and he is a previously treated patient with the required therapies. There are minor uncertainties regarding organ function and INR, but these do not significantly impact eligibility.

---

### [NCT06764485](https://clinicaltrials.gov/study/NCT06764485)

**A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge**

- **Sponsor**: Celgene
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC) which matches the trial condition.
- Patient has confirmed previous treatment with enzalutamide, fulfilling the treatment line criteria.
- Patient has no brain metastases, meeting the exclusion criteria.

**Assessment:**
> The patient's cancer type matches the trial's focus on mCRPC, and he has had prior treatment with an androgen receptor pathway inhibitor, which is required. There are no conflicts noted with eligibility criteria, leading to high confidence in potential eligibility.

---

### [NCT06691984](https://clinicaltrials.gov/study/NCT06691984)

**A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy**

- **Sponsor**: Amgen
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC).
- Patient is 72 years old.
- Patient has ECOG status of 1.
- Patient has prior progression on enzalutamide and docetaxel (meets prior therapy criteria).
- Patient has a prior treatment with only one taxane therapy in the mCRPC setting (docetaxel).
- Patient has a germline BRCA2 mutation.
- Patient has no brain metastases.

**? Uncertainties:**
- Adequate organ function is unspecified.
- Life expectancy assessment is not provided.
- No exact confirmation on testosterone level (< 50 ng/dL) is provided.

**Assessment:**
> The patient's disease type matches the trial's indication of metastatic castration-resistant prostate cancer (mCRPC). The patient is previously treated, which aligns with the trial's design. The supporting factors confirm compliance with key eligibility criteria, although a few minor uncertainties exist regarding organ function and life expectancy assessment.

---

### [NCT00923221](https://clinicaltrials.gov/study/NCT00923221)

**Collection of Blood From Patients With Prostate Cancer**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of prostate cancer
- Patient is 72 years old (above 18 years)
- ECOG status of 1

**Assessment:**
> The patient's cancer type is prostate cancer, which matches the trial's focus. The patient is above 18 years old, has a confirmed diagnosis of prostate cancer, and has an ECOG status of 1, aligning well with the inclusion criteria. There are no conflicts or uncertainties identified.

---

### [NCT04898634](https://clinicaltrials.gov/study/NCT04898634)

**A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed adenocarcinoma of the prostate which has spread to other body parts
- Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy (enzalutamide)
- ECOG performance status of 1

**Assessment:**
> The patient's condition (metastatic prostate cancer) matches the trial indication. The patient has prior treatment (enzalutamide) and meets the ECOG status criterion. No conflicting criteria identified.

---

### [NCT04995198](https://clinicaltrials.gov/study/NCT04995198)

**PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness**

- **Sponsor**: Prostate Cancer Clinical Trials Consortium
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC)
- Patient has a confirmed germline BRCA2 mutation
- Patient resides in the United States
- Patient has documented disease evidenced by rising PSA levels

**Assessment:**
> The patient's cancer type matches the trial's indication of prostate cancer, and the patient has undergone prior therapies, which aligns with the trial's acceptance of previously treated patients. The patient meets the age criteria and resides in the United States, fulfilling the necessary geographical criteria.

---

### [NCT05519449](https://clinicaltrials.gov/study/NCT05519449)

**A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer**

- **Sponsor**: Janux Therapeutics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Male
- Age 72
- Histologically confirmed prostate cancer (mCRPC)
- Progressed after at least one novel anti-androgen therapy (enzalutamide)
- Progressed after at least one taxane regimen (docetaxel)
- Germline BRCA2 mutation confirmed
- ECOG status 1
- No brain metastases
- Good functional status despite bone disease

**? Uncertainties:**
- Adequate organ function is not explicitly confirmed

**Assessment:**
> The patient's prostate cancer type matches the trial's focus on metastatic castration-resistant prostate cancer (mCRPC). He has progressed after required treatments and meets age and ECOG status criteria. The only uncertainty is regarding adequacy of organ function, which is not explicitly confirmed.

---

### [NCT06046040](https://clinicaltrials.gov/study/NCT06046040)

**Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: University of Pennsylvania
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 72
- Sex: male
- Cancer type: metastatic castrate-resistant prostate cancer (mCRPC)
- Prior therapies: enzalutamide, docetaxel
- ECOG Status: 1

**? Uncertainties:**
- Castrate levels of testosterone (<50 ng/dL)
- Organ function labs: serum creatinine, ALT/AST, bilirubin, LVEF, pulmonary reserve, hematologic reserve

**Assessment:**
> The patient's cancer type matches the trial's indication of mCRPC and he has received prior treatments as required. Although there are uncertainties regarding organ function and testosterone levels, he meets the other criteria clearly.

---

### [NCT05806814](https://clinicaltrials.gov/study/NCT05806814)

**Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)**

- **Sponsor**: University of Oklahoma
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient is male, aged 72, meeting age criterion (â‰¥ 18 years)
- Patient has prostate cancer with a history of metastasis, matching trial condition
- ECOG performance status of 1 allows for participation
- Patient has a life expectancy of â‰¥ 6 months

**Assessment:**
> The patient's prostate cancer diagnosis aligns with the trial's focus on metastatic castration-resistant prostate cancer. The patient meets all critical eligibility criteria including age, ECOG status, and metastatic status. There are no reported conflicts with the exclusion criteria, and the treatment line aligns with previously treated populations.

---

### [NCT06801236](https://clinicaltrials.gov/study/NCT06801236)

**A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)**

- **Sponsor**: Acerand Therapeutics (Hong Kong) Limited
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC)
- ECOG status is 1
- Patient has provided written informed consent
- Patient has a life expectancy of at least 6 months

**? Uncertainties:**
- Adequate organ function and bone marrow function are not explicitly stated
- Concomitant use of medications or herbal supplements is not stated

**Assessment:**
> The patient's cancer type matches the trial's focus on mCRPC. The patient has prior therapy, which aligns with the inclusion criteria for those who are difficult to treat or intolerant to standard treatment. The patient's ECOG status and life expectancy also meet the trial requirements. However, organ function and concomitant medication details are not provided, leading to minor uncertainties.

---

### [NCT06395519](https://clinicaltrials.gov/study/NCT06395519)

**A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies**

- **Sponsor**: 858 Therapeutics, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Male patient over 18 years of age
- Histologically confirmed metastatic castration-resistant prostate cancer (mCRPC)
- Progression on systemic therapies including enzalutamide and docetaxel
- Germline BRCA2 mutation confirmed
- ECOG status of 1
- No brain metastases
- Life expectancy of at least 3 months is likely supported by clinical details

**Assessment:**
> The patient's cancer type matches the trial's indication as it includes prostate cancer, and he has a confirmed BRCA2 mutation. The patient has progressed after prior therapies, which is in line with the trial's inclusion criteria for previously treated patients. All critical eligibility criteria are supported by explicit patient information.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic prostate cancer, which is an eligible condition for the trial.
- Patient is currently progressing on a regimen of standard of care therapy (olaparib).
- Patient's ECOG status is 1.

**? Uncertainties:**
- No information on archival tissue or biopsy availability.

**Assessment:**
> The patient's cancer type matches the trial criteria as he has metastatic prostate cancer. He is currently progressing on a standard of care therapy, meeting treatment line criteria. His ECOG status is acceptable, but there is some uncertainty around tissue and biopsy criteria.

---

### [NCT04890613](https://clinicaltrials.gov/study/NCT04890613)

**Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation**

- **Sponsor**: Senhwa Biosciences, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has prostate cancer, which is included as a target indication in the trial.
- Patient has a documented germline BRCA2 mutation, meeting the biomarker requirement.
- ECOG status of 1 meets the performance status criteria.
- Patient is 72 years old, above the minimum age requirement of 18.
- No brain metastases present.

**? Uncertainties:**
- Organ function lab results not provided (e.g., ANC, platelets, hemoglobin, creatinine clearance, liver function tests, albumin).

**Assessment:**
> The patient's prostate cancer and documented germline BRCA2 mutation align with the trial's focus on advanced solid tumors with specific genetic mutations. With an ECOG status of 1 and no brain metastases, the patient is physically capable of participating. While we lack specific organ function labs, the overall profile fits well within acceptable trial parameters.

---

### [NCT05107674](https://clinicaltrials.gov/study/NCT05107674)

**A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types**

- **Sponsor**: Nurix Therapeutics, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 72, which is â‰¥ 18 years.
- ECOG status is 1.
- Current condition is metastatic castration-resistant prostate cancer (mCRPC) which is included in the trial conditions.
- Patient has received prior therapy (enzalutamide, docetaxel, olaparib) and is not treatment-naive.

**Assessment:**
> The patient's cancer type, metastatic castration-resistant prostate cancer (mCRPC), aligns with the conditions studied in the trial. All major eligibility criteria including age and ECOG status are met. Though the patient is not treatment-naive, the trial does not specify strict first-line treatment eligibility, allowing for the possibility of previously treated candidates.

---

### [NCT06177171](https://clinicaltrials.gov/study/NCT06177171)

**A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors**

- **Sponsor**: Pamela Munster
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- The patient has metastatic castration-resistant prostate cancer (mCRPC), which matches the trial's focus on advanced solid tumors.
- The patient has a BRCA2 germline mutation, which qualifies under the trial's eligibility criteria.
- The patient's ECOG status is 1, which is acceptable.
- The patient has measurable disease with rising PSA after previous treatments.
- The patient has received prior PARP inhibitor (olaparib) without requiring toxicity-related dose reductions or experiencing allergies.

**? Uncertainties:**
- Organ function lab values (e.g., hemoglobin, neutrophil count, etc.) are not provided.
- Specifics on whether the patient has recovered from any adverse events due to prior anti-cancer therapy are not available.

**Assessment:**
> The patient's cancer type (mCRPC with BRCA2 mutation) aligns with the trial focus on HRR-mutated tumors. The patient is previously treated, which is acceptable as the trial is for both previously treated and treatment-naive patients. The patient meets most required criteria, but some organ function details are missing.

---

### [NCT06659614](https://clinicaltrials.gov/study/NCT06659614)

**Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease**

- **Sponsor**: Abramson Cancer Center at Penn Medicine
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed germline BRCA2 mutation
- ECOG status of 1
- Patient has prostate cancer

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer, which aligns with the trial's focus on prostate cancer and genetic predisposition. The patient's confirmed germline BRCA2 mutation fulfills the inclusion requirement for a pathogenic variant. The patient's ECOG status is acceptable, and there are no exclusion criteria affecting their eligibility.

---

### [NCT04946370](https://clinicaltrials.gov/study/NCT04946370)

**Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer**

- **Sponsor**: Weill Medical College of Cornell University
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 83%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC)
- ECOG status of 1
- Prior treatments include enzalutamide and docetaxel (acceptable as previously treated)
- Patient has normal functional status despite bone disease

**? Uncertainties:**
- Serum testosterone level is not provided
- Lab values for organ function (absolute neutrophil count, hemoglobin, platelet count, creatinine, bilirubin, AST/ALT levels) are not provided

**Assessment:**
> The patient's cancer type matches the trial's focus on prostate cancer, and they have previously been treated, which aligns with the trial's eligibility criteria for previously treated patients. However, there are some uncertainties regarding testosterone levels and organ function lab values.

---

### [NCT05413850](https://clinicaltrials.gov/study/NCT05413850)

**An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer**

- **Sponsor**: Blue Earth Therapeutics Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Male subject
- Age 72
- ECOG status 1
- History of metastatic castration-resistant prostate cancer (mCRPC)
- Prior therapies include enzalutamide and docetaxel
- BRCA2 germline mutation confirmed
- No brain metastases
- No visceral involvement
- Good functional status despite bone disease
- No bone pain requiring opioids

**? Uncertainties:**
- Serum testosterone level not provided
- Disease expression of PSMA confirmed on PSMA PET/CT scan not provided
- Recent imaging (CT/MRI, 99mTc bone scan) results not provided
- Blood count and serum biochemistry for organ function not provided

**Assessment:**
> The patient has metastatic castration-resistant prostate cancer, which matches the trial's disease focus. Additionally, the patient has received prior therapies consistent with the treatment line requirements for the trial. The patient meets several inclusion criteria but lacks specific information regarding testosterone levels and PSMA expression, leading to a high likelihood of eligibility with some uncertainties.

---

### [NCT06216249](https://clinicaltrials.gov/study/NCT06216249)

**A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)**

- **Sponsor**: Jonsson Comprehensive Cancer Center
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age: 72 (adult eligibility)
- ECOG status: 1
- Received at least one regimen of chemotherapy for mCRPC (docetaxel)
- Received at least one androgen-receptor signaling inhibitor (enzalutamide)
- Histopathology confirmed prostate cancer
- No brain metastases
- PSA response to prior treatment with olaparib

**? Uncertainties:**
- WBC, PLT, Hb, ANC values are not provided
- PSMA PET/CT eligibility is uncertain as it has not been stated if the patient underwent this within 8 weeks of planned first cycle.

**Assessment:**
> The patient's cancer type matches the trial's indication of metastatic castration-resistant prostate cancer (mCRPC). The patient has had prior treatments that align with the trial's requirements. However, the confirmation of PSMA PET/CT and certain lab values are missing, leading to a moderate level of confidence in the overall eligibility.

---

### [NCT06520345](https://clinicaltrials.gov/study/NCT06520345)

**A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment**

- **Sponsor**: Telix Pharmaceuticals (Innovations) Pty Limited
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age: 72
- Sex: male
- Cancer type: prostate cancer (adenocarcinoma)
- ECOG status: 1
- Prior therapies: enzalutamide, docetaxel, olaparib
- No brain metastases
- Metastatic disease: confirmed
- Castration-resistant prostate cancer: confirmed
- Disease progression on enzalutamide and docetaxel confirmed
- Good functional status despite bone disease
- PSA values: rising (72 ng/mL).

**? Uncertainties:**
- Need to confirm if serum/plasma testosterone level is <50 ng/dL at Screening
- Need to confirm evidence of PSMA positivity via 68Ga-PSMA-11 PET/CT scan
- Need to verify organ function lab results (platelets, neutrophils, hemoglobin, liver function, renal function)

**Assessment:**
> The patient's cancer type matches the trial's indication of metastatic castration-resistant prostate cancer (mCRPC), and the patient is previously treated, which aligns with the trial's criteria. There are some uncertainties regarding testosterone level and PSMA positivity which need to be addressed, but overall, the patient seems to likely qualify.

---

### [NCT06615752](https://clinicaltrials.gov/study/NCT06615752)

**A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients**

- **Sponsor**: Charles Drew University of Medicine and Science
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Male patient 72 years old
- Diagnosed with metastatic prostate cancer
- Confirmed progressive disease on enzalutamide and docetaxel
- Currently on docetaxel infusion

**? Uncertainties:**
- Adequate bone marrow function (ANC and platelet count not provided)
- Adequate liver function (total bilirubin, ALT, and AST not provided)
- Adequate renal function (serum creatinine level not provided)
- Life expectancy (the specific estimation is not provided)
- Consumption of tea or quercetin supplements during the study intervention period

**Assessment:**
> The patient's cancer type matches as he has metastatic castration-resistant prostate cancer, which is what the trial studies. The patient has received the required prior therapies, including docetaxel. There are some uncertainties about lab values and the specific dietary restrictions during the trial, but overall the patient likely qualifies.

---

### [NCT03460977](https://clinicaltrials.gov/study/NCT03460977)

**A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has metastatic castration-resistant prostate cancer (mCRPC) as required by the trial
- ECOG status of 1 meets the requirement of ECOG 0-2
- Patient is male, fulfilling the gender requirement for Part 3 of the trial

**? Uncertainties:**
- Adequate bone marrow, renal, and liver function (missing specific lab results)
- No prior enzalutamide within the last 4 weeks is required (patient used enzalutamide before but timing not explicitly mentioned)
- No specific details on patient blood pressure are provided, which is relevant for exclusion criteria related to uncontrolled hypertension

**Assessment:**
> The patient's condition aligns with the trial's focus on mCRPC. The ECOG status is acceptable, but there are uncertainties regarding specific organ function tests and recent treatment timelines that need further verification.

---

### [NCT06305598](https://clinicaltrials.gov/study/NCT06305598)

**Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

- **Sponsor**: Roswell Park Cancer Institute
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 70%

**âœ“ Supporting Factors:**
- Age is 72, which meets the age requirement (â‰¥ 18 years)
- ECOG status is 1, which meets the requirement (â‰¤ 2)
- Histologically confirmed prostate cancer
- Progressing on androgen ablative therapy (previous enzalutamide treatment)
- Prior treatment with at least one ARSI (enzalutamide) and one chemotherapy (docetaxel)
- No brain metastases
- Good functional status despite bone disease

**? Uncertainties:**
- Castrate level of blood testosterone is not provided, which is needed to assess eligibility
- Biopsiable disease status is not provided, making it unclear if adequate archival tissue is available
- Absolute neutrophil count and platelet count are not provided; unclear if they meet the minimum thresholds
- Total bilirubin levels and AST/ALT levels are not provided; unable to check if they meet institutional ULN
- Creatinine clearance (CrCl) is not provided; unsure if itâ€™s > 50 mL/min

**Assessment:**
> The patient's cancer type matches the trial's conditions of metastatic castration-resistant prostate cancer, and the patient is previously treated as required by the trial. However, there are several uncertainties regarding specific organ functions and laboratory values that need to be confirmed, preventing an absolute high confidence in eligibility.

---

### [NCT06101290](https://clinicaltrials.gov/study/NCT06101290)

**Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)**

- **Sponsor**: University of California, Davis
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 70%

**âœ“ Supporting Factors:**
- Age is 72, which is above the minimum required age of 18.
- ECOG status is 1, which is acceptable for the trial.
- Patient has prostate cancer, which is included in the trial conditions.
- Currently on systemic therapy (denosumab) and previously on approved therapies.

**? Uncertainties:**
- The status of disease progression with respect to the criteria of â‰¤ 5 progressing or new metastatic lesions is unclear.
- The ability to treat progressing lesions with locally ablative therapies is not confirmed.

**Assessment:**
> The patient has prostate cancer, matches the treatment line as he has received multiple prior therapies, and has an acceptable age and ECOG status. There are some uncertainties regarding the specifics of progression and treatment options for lesions.

---

### [NCT06228053](https://clinicaltrials.gov/study/NCT06228053)

**A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial**

- **Sponsor**: Syntrix Biosystems, Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 50%

**âœ“ Supporting Factors:**
- Diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
- Patient is currently on enzalutamide
- Rising PSA above the required level (72)
- ECOG status of 1 indicating good functional status
- Age is above 18
- Patient has a life expectancy of â‰¥ 6 months
- No brain metastases present
- Patient is willing to provide written informed consent

**âœ— Potential Conflicts:**
- Patient has prior treatment with docetaxel which is within the 4-week exclusion period before starting the study treatment.

**? Uncertainties:**
- Archival tumor tissue availability is unspecified
- Bone marrow and hepatic function laboratory values are not provided; therefore, they remain uncertainties.

**Assessment:**
> The patient has a diagnosis that directly aligns with the trial's focus on metastatic castration-resistant prostate cancer. However, the patient is excluded due to prior docetaxel treatment being within 4 weeks of starting the trial, which is a specific exclusion criterion.

---

## ðŸŸ¡ MEDIUM Likelihood (2 trials)

### [NCT06004661](https://clinicaltrials.gov/study/NCT06004661)

**An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.**

- **Sponsor**: Novartis Pharmaceuticals
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- ECOG status of 1 is acceptable
- Patient has documented progressive mCRPC
- Patient has a BRCA2 germline mutation

**âœ— Potential Conflicts:**
- No information on 68Ga-PSMA-11 PET/CT scan results
- No information on serum/plasma testosterone levels
- Patient's renal function (eGFR) is not provided

**? Uncertainties:**
- Patient's eGFR (kidney function)
- Results of the 68Ga-PSMA-11 PET/CT scan
- Serum/plasma testosterone levels

**Assessment:**
> Patient has metastatic castration-resistant prostate cancer (mCRPC), which matches the trial's disease focus. However, uncertainties regarding specific trial eligibility criteria, such as PET scan results and renal function, prevent a higher confidence level in eligibility.

---

### [NCT04221542](https://clinicaltrials.gov/study/NCT04221542)

**A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer**

- **Sponsor**: Amgen
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Confirmed diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
- ECOG status of 1
- No brain metastases
- Reported good functional status

**âœ— Potential Conflicts:**
- Patient has received more than 2 systemic therapies (including enzalutamide, docetaxel, and olaparib)
- Patient has received prior enzalutamide, making him ineligible for parts requiring no prior antiandrogens

**? Uncertainties:**
- Organ function lab results (e.g., hematological function, renal function, hepatic function, cardiac function)
- Total serum testosterone level
- Progressive disease details not fully specified (PSA rising must meet specific criteria)

**Assessment:**
> The patient's cancer type aligns with the trial, but conflicts arise from prior treatment history, which disqualifies him as he exceeds the number of allowed non-hormonal therapy line treatments and has previously received enzalutamide. Additional testing information is needed to ascertain eligibility.

---

## Excluded (64 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT03851445](https://clinicaltrials.gov/study/NCT03851445) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04145375](https://clinicaltrials.gov/study/NCT04145375) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04573231](https://clinicaltrials.gov/study/NCT04573231) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06049355](https://clinicaltrials.gov/study/NCT06049355) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06253130](https://clinicaltrials.gov/study/NCT06253130) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00756665](https://clinicaltrials.gov/study/NCT00756665) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03568630](https://clinicaltrials.gov/study/NCT03568630) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04970056](https://clinicaltrials.gov/study/NCT04970056) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05587439](https://clinicaltrials.gov/study/NCT05587439) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05625529](https://clinicaltrials.gov/study/NCT05625529) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06151223](https://clinicaltrials.gov/study/NCT06151223) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06242470](https://clinicaltrials.gov/study/NCT06242470) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06538636](https://clinicaltrials.gov/study/NCT06538636) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06710379](https://clinicaltrials.gov/study/NCT06710379) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06883838](https://clinicaltrials.gov/study/NCT06883838) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06995898](https://clinicaltrials.gov/study/NCT06995898) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT03678025](https://clinicaltrials.gov/study/NCT03678025) | SWOG Cancer Research | Patient must have an intact prostate. The patient has metastatic castration-resistant prostate cancer (mCRPC), suggesting possible prior treatments impacting the prostate. |
| [NCT05168618](https://clinicaltrials.gov/study/NCT05168618) | University of Utah | Patient has measurable bone disease whereas trial requires non-measurable disease outside the pelvis. |
| [NCT05498272](https://clinicaltrials.gov/study/NCT05498272) | Rana McKay, MD | Trial excludes patients with prior treatments not allowed: enzalutamide and olaparib are both listed as prior treatments, which are excluded. |
| [NCT06029998](https://clinicaltrials.gov/study/NCT06029998) | University of Utah | Patient has received systemic chemotherapy (docetaxel) for mCRPC, which disqualifies them due to the exclusion criteria. |
| [NCT06161506](https://clinicaltrials.gov/study/NCT06161506) | National Cancer Inst | Patient has metastatic castration-resistant prostate cancer, while the trial is studying urinary incontinence related to prostate cancer treatment, which is not a direct match. |
| [NCT06145633](https://clinicaltrials.gov/study/NCT06145633) | Fred Hutchinson Canc | Patient has prior systemic therapy with enzalutamide, docetaxel, and olaparib which may not fit the trial's criteria since it does not specify acceptance of those particular therapies. |
| [NCT06402331](https://clinicaltrials.gov/study/NCT06402331) | Fusion Pharmaceutica | The trial requires prior treatment with lutetium-PSMA therapy, which the patient has not received. |
| [NCT06568562](https://clinicaltrials.gov/study/NCT06568562) | University of Utah | Patient has not received 177Lu-PSMA-617, which is a requirement for trial eligibility |
| [NCT06785636](https://clinicaltrials.gov/study/NCT06785636) | Pathos AI, Inc. | Patient has received prior systemic therapy (enzalutamide, docetaxel, olaparib) whereas the trial may require treatment-naive patients. |
| [NCT06780670](https://clinicaltrials.gov/study/NCT06780670) | Novartis Pharmaceuti | Patient has not received [177Lu]Lu-PSMA targeted therapy as required by the trial inclusion criteria. |
| [NCT06855277](https://clinicaltrials.gov/study/NCT06855277) | Novartis Pharmaceuti | Patient has received prior treatment with ARPI (enzalutamide), which is specifically disallowed for mCRPC in this trial. |
| [NCT06894511](https://clinicaltrials.gov/study/NCT06894511) | Novartis Pharmaceuti | Patient has prior therapies (enzalutamide, docetaxel, olaparib) whereas the trial is for patients who have progressed on ARPI in the BCR-non mHSPC, mHSPC, or nmCRPC setting but may allow only one prior ARPI. |
| [NCT06972628](https://clinicaltrials.gov/study/NCT06972628) | Ebrahim S Delpassand | Patient does not have a 'super scan' pattern on bone scan as the requirement specifies |
| [NCT04254133](https://clinicaltrials.gov/study/NCT04254133) | Fred Hutchinson Canc | Patient is a resident of the United States but not specifically in Washington state, which is a requirement. |
| [NCT04552509](https://clinicaltrials.gov/study/NCT04552509) | Linda Chan, MD | Patient has metastatic castration-resistant prostate cancer (mCRPC) but trial does not specify if it includes advanced stages beyond localized prostate cancer. |
| [NCT04992728](https://clinicaltrials.gov/study/NCT04992728) | University of Califo | Prior treatment for prostate cancer (enzalutamide, docetaxel, olaparib) conflicts with eligibility criteria that excludes prior treatments. |
| [NCT05079698](https://clinicaltrials.gov/study/NCT05079698) | Memorial Sloan Kette | Patient has metastatic castration-resistant prostate cancer (mCRPC), while the trial is for hormone sensitive, oligometastatic prostate cancer. |
| [NCT05155501](https://clinicaltrials.gov/study/NCT05155501) | Weill Medical Colleg | Patient has metastatic castration-resistant prostate cancer (mCRPC) while the trial requires clinically localized prostate cancer. |
| [NCT06355336](https://clinicaltrials.gov/study/NCT06355336) | Cincinnati Cancer Ad | Patient has metastatic castration-resistant prostate cancer (mCRPC) which does not match the trial's inclusion criteria specifying diagnosis since January 1st, 2023. |
| [NCT02000089](https://clinicaltrials.gov/study/NCT02000089) | Johns Hopkins Univer | Patient has prostate cancer; trial is for pancreas cancer and related conditions, which do not match. |
| ... | ... | *and 28 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| BRCA2 germline mutation | manual | 1.0 |
| prostate cancer | manual | 1.0 |
| BRCA2 germline mutation prostate cancer | manual | 1.0 |
| BRCA2 germline mutation mCRPC | llm | 0.9 |
| BRCA2 mutation metastatic castration-resistant prostate cancer | llm | 0.9 |
| mCRPC | llm | 0.8 |
| metastatic castration-resistant prostate cancer | llm | 0.8 |
| BRCA2 mutation | llm | 0.9 |
| BRCA2mutation | llm | 0.8 |
| BRCA2-mutation | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Life expectancy estimate** - many trials require â‰¥3 months
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
